Log in to save to my catalogue

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Li...

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Li...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_karger_primary_533859

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab

About this item

Full title

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab

Publisher

Basel, Switzerland: S. Karger AG

Journal title

Oncology, 2024-03, Vol.102 (3), p.239-251

Language

English

Formats

Publication information

Publisher

Basel, Switzerland: S. Karger AG

More information

Scope and Contents

Contents

Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic...

Alternative Titles

Full title

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_karger_primary_533859

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_karger_primary_533859

Other Identifiers

ISSN

0030-2414

E-ISSN

1423-0232

DOI

10.1159/000533859

How to access this item